Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
NYSE: BHVN · IEX Real-Time Price · USD
35.98
+1.27 (3.66%)
At close: Jul 19, 2024, 4:00 PM
35.91
-0.07 (-0.19%)
After-hours: Jul 20, 2024, 12:58 PM EDT
BHVN Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for BHVN stock have an average target of 54.71, with a low estimate of 36 and a high estimate of 60. The average target predicts an increase of 52.06% from the current stock price of 35.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 18, 2024.
Analyst Ratings
The average analyst rating for BHVN stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $59 | Buy | Reiterates | $59 | +63.98% | Jun 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $59 | Strong Buy | Reiterates | $59 | +63.98% | May 30, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $63 → $59 | Strong Buy | Maintains | $63 → $59 | +63.98% | May 13, 2024 |
| UBS | UBS | Strong Buy Maintains $59 → $60 | Strong Buy | Maintains | $59 → $60 | +66.76% | Apr 23, 2024 |
Financial Forecast
Revenue This Year
41.19M
Revenue Next Year
10.21M
from 41.19M
Decreased by -75.21%
EPS This Year
-3.70
from -5.73
EPS Next Year
-7.47
from -3.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.0M | 52.5M | 443.3M | 645.1M | 1.4B |
| Avg | 10.2M | 11.4M | 160.8M | 446.5M | 901.6M |
| Low | n/a | n/a | n/a | 186.2M | 465.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 414.3% | 3,782.3% | 301.2% | 223.6% |
| Avg | - | 11.9% | 1,308.2% | 177.7% | 101.9% |
| Low | - | - | - | 15.8% | 4.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.90 | -5.50 | -3.86 | -2.91 | -0.25 |
| Avg | -7.47 | -6.80 | -5.65 | -2.83 | -0.24 |
| Low | -8.76 | -7.78 | -7.99 | -2.71 | -0.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.